← Leaderboards
Ricardo Spielberger
University Of Southern California
$252,729
Attributed
$252,729
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $31.6K · FY2005–07$50K$37.5K$25K$12.5K$0
'05
'06
'07
Funding mix
By agency
NIH$252,729 · 4
By mechanism
M01$252,729 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Don J Diamond$24,317,616
- John A Zaia$8,207,353
- Kenneth I. Weinberg$11,172,423
- Donald B Kohn$24,055,774
- Amrita Krishnan$301,778
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationClinical Trial Phase ICell CycleLeukemiaEnzyme ActivityInjection /InfusionNeoplasm /Cancer ChemotherapyPharmacokineticsTopotecanDna MethylationMethyltransferaseGanciclovirCytomegalovirusChemopreventionLatent Virus InfectionIntravenous AdministrationBone Marrow TransplantationOral AdministrationDisease /Disorder Prevention /ControlHematopoietic Tissue TransplantationDetection
Grant awards (11)
A PHASE III MULTICENTER STUDY OF VALGANCICLOVIR$2,907
M01 · FY2007 · RR · contact PI
A PHASE III MULTICENTER STUDY OF VALGANCICLOVIR$31,573
M01 · FY2006 · RR · contact PI
A PHASE III MULTICENTER STUDY OF VALGANCICLOVIR$24,791
M01 · FY2005 · RR
A Phase III Multicenter Study of Valganciclovir$2,141
M01 · FY2004 · RR
INFUSION OF ICRF 187 FOLLOWED BY INFUSION OF TOPOTECAN IN LEUKEMIA$0
M01 · FY2002 · RR
INFUSION OF ICRF 187 FOLLOWED BY INFUSION OF TOPOTECAN IN LEUKEMIA$155,764
M01 · FY2001 · RR
INFUSION OF ICRF 187 FOLLOWED BY INFUSION OF TOPOTECAN IN LEUKEMIA$0
M01 · FY2001 · RR
INFUSION OF ICRF 187 FOLLOWED BY INFUSION OF TOPOTECAN IN LEUKEMIA$35,553
M01 · FY2000 · RR
INFUSION OF ICRF 187 FOLLOWED BY INFUSION OF TOPOTECAN IN LEUKEMIA$0
M01 · FY2000 · RR
INTRAVENOUS THEN ORAL GANCICLOVIR IN CMV REACTIVATION$0
M01 · FY2000 · RR
INTRAVENOUS THEN ORAL GANCICLOVIR IN CMV REACTIVATION$0
M01 · FY2000 · RR